Scientists at UCLA have engineered cancer-fighting T cells from cord blood stem cells that attack solid tumors by targeting internal protein fragments, creating uniform batches that bypass the need for custom patient treatments while avoiding graft-versus-host disease. Published in Cell Reports Medicine, the scalable platform uses blood stem cells from donated cord blood to produce off-the-shelf therapies for hard-to-reach malignancies.
UCLA Engineers Off-The-Shelf T Cells From Cord Blood
Bypassing the Custom Manufacturing Bottleneck
Traditional T-cell therapies require doctors to harvest a patient’s own immune cells and genetically reprogram them individually. That custom manufacturing cycle takes weeks and runs into high costs. To solve this bottleneck, researchers at the UCLA Broad Stem Cell Research Center and the UCLA Health Jonsson Comprehensive Cancer Center looked upstream to blood stem cells found in cord blood, which naturally generate every type of blood and immune cell in the human body.
https://x.com/UCLA/status/2097822400058405187
Co-senior author Lili Yang, a professor of microbiology, immunology and molecular genetics, noted that the platform moves researchers closer to treatments that are manufactured in advance and frozen for immediate use.
When scientists introduced a gene for a specific receptor into these immature stem cells, the cells matured into T cells that all carried the exact same tumor-targeting receptor. This contrasts with conventional donor-derived T cells, which typically carry a random assortment of natural receptors that require extensive gene editing to prevent them from attacking healthy tissue.
Unlocking Solid Tumors via Internal Protein Fragments
Solid tumors have historically resisted standard immunotherapies because most of their abnormal proteins remain hidden inside the cell rather than sitting on the outer surface.
While CAR T-cell therapy can only spot proteins naturally displayed on the exterior of a cancer cell, T-cell receptor (TCR) therapy can capture small protein fragments originating from inside the cell and carried to the surface like name tags.
The UCLA team engineered their stem cells to recognize NY-ESO-1, a specific protein found across numerous solid tumors. By locking in this single receptor before the stem cells fully differentiate, the resulting cells—named AlloESO-T cells—focus exclusively on the intended target without generating the random receptors that trigger graft-versus-host disease.
Preclinical Success in Ovarian Cancer and Melanoma Models
In laboratory tests using mouse models of ovarian cancer and melanoma, investigators administered a single dose of the engineered AlloESO-T cells. The treatment successfully kept tumors in check and extended survival rates, according to the study findings. Furthermore, these manufactured cells avoided the toxic side effects observed when conventional donor T cells were tested in the same animal models.
Co-first author Yichen (John) Zhu, a graduate student in the UCLA Broad Stem Cell Research Center Training Program, explained that because stem cells are undifferentiated, directing their receptor profile early ensures uniform targeting across the entire engineered batch. The approach establishes a foundation for renewable, standardized immunotherapy manufacturing that could eventually scale down production timelines and expand patient access.
Keep reading